Acepodia Secures FDA Approval for ACE1831 in IgG4-Related Disease
Overview
Acepodia has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for ACE1831.
IgG4-Related Disease
IgG4-Related Disease (IgG4-RD) is a rare autoimmune condition characterised by inflammation and fibrosis in multiple organs, caused by elevated IgG4 antibodies.
Treatment focuses on controlling inflammation and preventing organ damage.
This marks the company’s entry into autoimmune disease research, targeting IgG4-related disease (IgG4-RD), a multi-organ fibro-inflammatory condition.
IND Clearance: Acepodia
The IND clearance enables Acepodia to evaluate the safety and effectiveness of ACE1831 in patients with IgG4-RD.
The therapy employs bioorthogonal chemistry to attach CD20-targeting antibodies to gamma delta T cells, resulting in a scalable, off-the-shelf treatment that avoids genetic modification.
This approach aims to reduce the risks associated with CAR-T cell therapies, such as T cell malignancies.
ACE1831 is also undergoing a Phase 1 trial for non-Hodgkin's lymphoma (NHL).
Acepodia’s Treatment Strategy
Acepodia’s treatment strategy is based on evidence suggesting that deeper B cell depletion may provide longer remission in autoimmune diseases.
The company has collaborated with global experts in IgG4-RD research to develop this innovative approach.
About the Trial
The upcoming Phase 1b/2a study will be conducted in partnership with Pfizer Ignite, a platform that supports biotech firms with resources and expertise to advance new medicines.
The study will be led by a team at Massachusetts General Hospital, with a focus on assessing the potential of ACE1831 for improved disease control and reduced side effects compared to existing cell-based therapies.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!